New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2013
08:03 EDTTKPYY, AFFYAnemia drug had side effects soon after it went on the market, WSJ reports
As the FDA evaluates the anemia drug Omontys, used in kidney dialysis patients, life-threatening reactions to it began appearing within months of when the treatment went on the market, according to a review of regulatory records, reports the Wall Street Journal. The drug, from Affymax Inc. (AFFY) and Takeda Pharmaceutical Co. (TKPYY), was linked to allergic reactions and respiratory distress beginning in August 2012, soon after it went on the U.S. market in late April. Reference Link
News For AFFY;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
16:24 EDTAFFYAffymax adopts tax benefit preservation plan
Affymax announced that its board has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss carryforwards, or NOLs, in relation to the potential limitations under Section 382 of the Internal Revenue Code. The company had federal NOLs totaling approximately $481M at December 31, 2013, a substantial portion of which are limited due to a prior “ownership change”. The company’s use of the remaining NOLs could be substantially limited if the company experiences another “ownership change”. In general, an ownership change occurs if there is a cumulative change in a company’s ownership by “5% shareholders” that increases by more than 50 percentage points over the lowest percentage owned by such stockholders at any time during the prior three years on a rolling basis. The company noted that the Rights Plan is designed to serve the interests of all stockholders by helping to protect the company’s ability to use its NOLs to offset future tax liabilities and is similar to plans adopted by other companies with significant tax attributes.
16:22 EDTAFFYAffymax announces 5c per share special distribution
Subscribe for More Information
16:20 EDTAFFYAffymax appoints Jonathan Couchman as CEO
The Affymax board appointed Jonathan M. Couchman as a Class I director of the company and as its president and CEO, and the remaining members of the board have resigned. The company, under the leadership of Couchman, will continue its evaluation of strategic alternatives.
November 19, 2014
07:52 EDTTKPYYInforma Business Information to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use